Sophoflavescenol
| Code | Size | Price |
|---|
| TAR-TN2217-5mg | 5mg | £598.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃
Documents
Further Information
Bioactivity:
Sophoflavescenol is a mixed inhibitor of PDE5 with a K(i) value of 0.005 microM. Sophoflavescenol has antioxidant, anti-inflammatory, and apoptotic effects , these effects might contribute to the antitumor activity without severe side effects. Sophoflavescenol exerts notable anti-inflammatory activity by inhibiting nitric oxide generation and tert-butylhydroperoxide-induced ROS generation rather than inhibiting nuclear factor kappa B activation in RAW 264.7 cells.
CAS:
216450-65-6
Formula:
C21H20O6
Molecular Weight:
368.385
Pathway:
Neuroscience; ; Metabolism
Purity:
0.9965
SMILES:
COc1cc(O)c(CC=C(C)C)c2oc(c(O)c(=O)c12)-c1ccc(O)cc1
Target:
Beta-Secretase; BACE; PDE; AChR; AChE
References
Anti-tumorigenic activity of sophoflavescenol against Lewis lung carcinoma in vitro and in vivo.Arch Pharm Res. 2011 Dec;34(12):2087-99.